Vaccine Storage and Packaging Market Size, Share & Analysis 2031

A vital component of vaccination is the proper handling, packing, and storage of vaccines. The storage, packing, and handling of vaccines can contribute to the effectiveness of infectious disease campaigns. A vaccination loses efficacy or, in some situations, becomes inert when stored in extreme heat or cold, making its use risky. Most vaccines require refrigeration for storage between 2 and 8 degrees Celsius. Since vaccines must travel across the globe without losing their effectiveness, effective cold chain storage is crucial while in transit. Moreover, the vaccine should be packaged in a precisely planned and produced packaging medium, such as vials, ampoules, or corrugated boxes. All three levels of vaccine packaging—the primary (vials, ampoules, etc.), secondary (vaccine carton boxes), and tertiary (vaccine bags)—are included (insulated outer packaging layer).

Market Dynamics

Prevalence of Infectious Diseases and Immunology Disorders Drives the Global Market

The rapid spread of dangerous illnesses like SARS, Ebola, and HIV in recent years has brought attention to the need for worldwide pandemic preparation, which has sped up the development and wide distribution of vaccinations. Because of the situation's urgency, pharmaceutical companies are compelled to accelerate the process of producing vaccines. As a result, vaccines must be kept in storage from when they are created until they are administered. A serious infectious disease of the upper respiratory system is diphtheria. More than 16,000 cases of diphtheria were reported to the WHO by nations in 2018, but there are probably many more. The resurgence and prevalence of these infectious illnesses are forcing vaccine manufacturers to scale up production, which in turn is fueling demand for vaccine freezers to preserve vaccines and vaccine packaging materials and expanding the market.

Strong Portfolio of Key Companies for the COVID-19 Vaccine Creates Tremendous Opportunities

Manufacturers are working on developing vaccinations to stop the COVID-19 epidemic as it spreads violently worldwide. The COVID-19 vaccinations must be handled and kept properly because they are temperature-sensitive, ensuring their potency and shelf life. Indian glass vial manufacturers are prepared to supply pharmaceutical firms with COVID-19 vaccines and medications in response to any prospective demand. There are enough glass bottles to store billions of doses of the COVID-19 vaccine, which worries global health experts. With a 3 billion vial, ampoule, and syringe production capability, Schott Kaisha is a joint venture between the Indian business KAISHA MANUFACTURERS and the German specialty glass manufacturer Schott. Schott is one of the biggest producers of borosilicate glass for creating tubular vials and ampoules. Corning, Nipro, and Schott are the top producers of tubular glass worldwide. Since there are many cold storage and packaging suppliers for the COVID-19 vaccine, plenty of opportunities will fuel the expansion of the worldwide vaccine storage and packaging market.

Regional Analysis

Europe is the most significant global vaccine storage and packaging market shareholder and is anticipated to exhibit a CAGR of 7.67% during the forecast period. The demand for the COVID-19 vaccine, rising acceptance and awareness among the populace, and expanding government initiatives are driving the growth of the worldwide vaccine storage and packaging market in Europe. In addition, Germany had more than 1 million doses of unused vaccines on hand when the need for them was so great, partly due to people's reluctance to use them. All vaccinations must be appropriately maintained and distributed in a cold working chain because they are all heat-sensitive. The WHO and Europe support examining national cold chains and logistics systems to guarantee the caliber of cold chains in the WHO European zone. These evaluations draw attention to system management components that require development. These needs are being met at the regional and national levels through targeted training seminars on vaccine inventory management, monitoring storage processes, maintenance of the cold chain, equipment requirements, and other relevant issues, as well as vaccine and cold chain management.

North America is estimated to exhibit a CAGR of 7.88% over the forecast period. The population of North America makes up 4.73% of the total global population. In 2021, there were 11.813 births for every 1000 persons in North America. With more infants in the region, there is an increased need for immunization. The best defense for your child against many hazardous diseases is immunization. In addition, Tetanus, pertussis, diphtheria, polio, Haemophilus influenzae type B, rotavirus, measles, mumps, hepatitis B, pneumococcal and meningococcal infections, rubella, chickenpox, and human papillomavirus are among the diseases that are prevented by immunizations in Canada. Furthermore, vaccination against influenza (flu) is advised yearly for kids older than six months. As a result, the global vaccine storage and packaging market is expanding due to the increasing demand for vaccinations.

Key Highlights

The global vaccine storage and packaging market was valued at USD 4,139.57 million in 2022. It is estimated to reach USD 8,220.01 million by 2031, growing at a CAGR of 7.92% during the forecast period (2023–2031).
Based on type, the global vaccine storage and packaging market is bifurcated into vaccine packaging and vaccine storage. The vaccine packaging segment dominates the global market and is projected to exhibit a CAGR of 7.71% over the forecast period.
Based on the end-user, the global vaccine storage and packaging market is segmented into healthcare facilities, pharma and biotech companies, and others. The pharma and biotech companies segment owns the highest market share and is estimated to exhibit a CAGR of 8.42% during the forecast period.
Europe is the most significant global vaccine storage and packaging market shareholder and is anticipated to exhibit a CAGR of 7.67% during the forecast period.